Abemaciclib, an anti-cancer drug, added to Australia's Pharmaceutical Benefits Scheme for treating certain types of breast cancer.
Abemaciclib, an anti-cancer drug developed by Eli Lilly, has been added to the Australian Pharmaceutical Benefits Scheme for treating certain types of breast cancer, specifically metastatic HR+/HER2- cases and high-risk early-stage breast cancer. First studied in 2014, the drug is a cyclin-dependent kinase inhibitor targeting CDK4 and CDK6 for cell division and DNA replication. Abemaciclib is also being investigated for potential use in gastrointestinal, blood, and brain cancers.
May 07, 2024
3 Articles